Hepatofugal Flow Management

Introduction to Hepatofugal Flow Treatment

The primary treatment for hepatofugal flow is directed at the underlying cause, most commonly portal hypertension from cirrhosis, using medical management of portal hypertension complications, with consideration for TIPS or liver transplantation in refractory cases, as recommended by the American Association for the Study of Liver Diseases 1, 2

Variceal bleeding should be managed with vasoactive drugs, endoscopic band ligation, and prophylactic antibiotics, according to the European Association for the Study of the Liver 5
Ascites should be treated with salt restriction, diuretics, and monitoring of renal function and electrolytes, as suggested by the American Association for the Study of Liver Diseases 3, 6
Hepatic encephalopathy should be treated with standard lactulose and rifaximin therapy, as recommended by the European Association for the Study of the Liver 7

If hepatofugal flow is associated with hepatic venous outflow obstruction, anticoagulation should be initiated immediately with low molecular weight heparin, transitioning to warfarin with a target INR of 2-3, continued indefinitely, as recommended by the American College of Chest Physicians 1

For short-segment venous stenoses in Budd-Chiari syndrome, angioplasty or stenting can re-establish physiological drainage, as suggested by the Society of Interventional Radiology 1
TIPS should be considered in patients unresponsive to medical therapy or not candidates for angioplasty/stenting, with a reported success rate of approximately 65% in patients with Budd-Chiari syndrome, according to the American Association for the Study of Liver Diseases 1, 2

Orthotopic liver transplantation is the only definitive curative option for severe portal hypertension with hepatofugal flow refractory to other treatments, with a 5-year survival rate exceeding 80%, as reported by the American Association for the Study of Liver Diseases 1, 2, 3

Hepatic artery embolization should not be performed in patients with portovenous shunts or biliary symptoms, due to the high risk of complications, as warned by the Society of Interventional Radiology 3, 4
Anticoagulation should not be delayed in Budd-Chiari syndrome, as early treatment reduces thrombotic complications, according to the American College of Chest Physicians 1
TIPS should not be used indiscriminately in Fontan-associated liver disease, except in highly selected cases of severe uncontrolled variceal bleeding, as recommended by the European Association for the Study of the Liver 5